Konakion

Phytomenadione, the active ingredient in Konakion, is a Vitamin K presented as a sterile injectable solution for intramuscular, intravenous and oral use. It is employed to prevent and treat vitamin K deficiency bleeding, reverse anticoagulant therapy, and provide neonatal prophylaxis against hemorrhagic disease. GNH USA supplies Konakion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Konakion (phytomenadione) is used to address disorders of vitamin K‑dependent coagulation.

- Vitamin K deficiency bleeding: restores clotting factor activity to stop or prevent bleeding. - Anticoagulant reversal: rapidly counteracts the effects of warfarin or other vitamin K antagonists. - Neonatal hemorrhagic disease prophylaxis: provides newborns with the vitamin K needed to avoid early‑life bleeding.

Konakion may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Injection site pain or erythema. - Nausea or vomiting. - Diarrhea. - Transient headache. - Mild fever. - Elevated liver enzymes.

Serious or Rare Side Effects: - Anaphylactic or severe allergic reactions. - Hemolysis or hematuria. - Acute renal failure. - Severe hypotension. - Thrombosis or embolic events. - Persistent elevated bilirubin.

When using Konakion, clinicians should observe several safety measures.

- Assess vitamin K status: verify deficiency or need for reversal before administration. - Monitor coagulation parameters: check PT/INR after dosing to gauge response. - Caution in liver disease: adjust use in patients with impaired hepatic synthesis of clotting factors. - Avoid in known hypersensitivity: discontinue if allergic reaction occurs. - Use with caution in newborns: follow neonatal dosing guidelines. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Konakion can interact with several medications, affecting its efficacy or safety.

Major Interactions (Avoid): - Broad‑spectrum antibiotics (e.g., cephalosporins) that impair vitamin K synthesis. - High‑dose vitamin E supplements, which may antagonize vitamin K activity.

Moderate Interactions (Monitor Closely): - Oral anticoagulants (warfarin, phenprocoumon): may require dose adjustment. - Lipid‑lowering agents (statins): potential modest effect on vitamin K metabolism. - Herbal products containing coumarins: may enhance anticoagulant effect. - Diuretics: monitor electrolyte balance when combined with vitamin K therapy.